Method for diagnosing liver toxicity with sex specific biomarkers

US8597875B2 · kind B2 · utility

Assignee

• BASF SE

Inventors

• Bennard van Ravenzwaay · Altrip, DE
• Werner Mellert · Haßloch, DE
• Georgia Coelho Palermo Cunha · São Paulo, BR
• Eric Fabian · Ludwigshafen, DE
• Volker Strauss · Bad Dürkheim, DE
• Hennicke Kamp · Bischheim, DE
• Tilmann B. Walk · Kleinmachnow, DE
• Ralf Looser · Berlin, DE
• Michael Manfred Herold · Berlin, DE
• Jan C. Wiemer · Berlin, DE
• Alexandre Prokoudine · Berlin, DE
• Edgar Leibold · Bischofswerda, DE

Key dates

• Filing date: May 26, 2009
• Grant date: Dec 3, 2013
• Expiry date: Oct 30, 2029

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A90/10
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The present invention pertains to the field of toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing liver toxicity. It also relates to a method of determining whether a compound is capable of inducing such liver toxicity in a subject and to a method of identifying a drug for treating liver toxicity. Furthermore, the present invention relates to a data collection comprising characteristic values of at least five metabolites, a data storage medium comprising said data collection, and a system and a device for diagnosing liver toxicity. Finally, the present invention pertains to the use of a group of metabolites or means for the determination thereof for the manufacture of a diagnostic device or composition for diagnosing liver toxicity in a subject. For each sex, a different metabolome pattern, i.e. a different set of analytes is disclosed. The liver toxicity markers are mainly selected from free fatty acids, but also include various phosphatidylcholines, Hydroxyphenylpyruvic acid, alpha-Tocopherol, Cholesterol, myo-Inositol-2-monophosphate, 4-Hydroxysphinganine, Ceramide (d18:1, C24:1), Ceramide (d18:2, C24:0), …